CN Patent

CN116270659A — 瑞马唑仑在制备治疗、减缓或处理骨癌疼痛的产品中的用途

Assigned to Shanghai Chest Hospital · Expires 2023-06-23 · 3y expired

What this patent protects

本发明属于医药技术领域，公开了瑞马唑仑或其药学上可接受的盐在制备治疗、减缓或处理骨癌疼痛的产品中的用途。本申请发现瑞马唑仑或其药学上可接受的盐具有明显骨癌疼痛缓解效果。

USPTO Abstract

本发明属于医药技术领域，公开了瑞马唑仑或其药学上可接受的盐在制备治疗、减缓或处理骨癌疼痛的产品中的用途。本申请发现瑞马唑仑或其药学上可接受的盐具有明显骨癌疼痛缓解效果。

Drugs covered by this patent

remimazolam-besylate (REMIMAZOLAM BESYLATE)

Patent Metadata

Patent number: CN116270659A
Jurisdiction: CN
Classification: —
Expires: 2023-06-23
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Chest Hospital
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.